Close
More
 
back_btn_arrow   Go back
Sign up or login to continue
New to Univadis?
Univadis is a free service for United States Healthcare Professionals.
*Please fill in all required fields.
By clicking "Sign up", I agree to the Terms of Use and Privacy Policy. and attest I am a healthcare professional.
Existing Univadis member:
Sign up or login to continue
Make more time for the moments that matter. Get expertly-curated updates and medical education, instantly.
New to Univadis?
Simply enter a password to join for free, if the information below is correct.
 
*Please enter a valid email address and password.
By clicking "Sign up", I agree to the Terms of Use and Privacy Policy. and attest I am a healthcare professional.
Forgot your password?  Reset now
Existing Univadis member:
Please login to continue
Welcome! Great to have you back.
*Your email address or password is incorrect.
Forgot your password?  Reset now
Reset your password
Please enter your email address, and we will send you a link to reset your password.
*Please enter a valid email address.

is already registered on Univadis

Is this you? Enter your password to continue.
The password you entered is incorrect. Please try again or choose a different option.
Forgot your password?  Reset now
Need more help? Please contact Member Service at support@univadis.com

is already registered on Univadis

Need more help? Please contact Member Service at support@univadis.com
Instructions to create a new password have been sent to the following email address:

For further assistance, please Contact Member Support
Thanks for Registering.
BreadCrumbsIncluded hideAllBreadCrumbs
American Society of Clinical Oncology
Chicago, Illinois, May 31 - June 4, 2019
News Coverage
Essential conference news
Successful in patients resistant to checkpoint inhibitors.
June 07, 2019
6-year follow-up of the phase 3 RESONATE trial.
June 07, 2019
OSLO-COMET shows similar long-term efficacy, less short-term morbidity.
June 07, 2019
Durable MRD negativity in peripheral blood.
June 07, 2019
Phase 2 trial shows no difference in PFS.
June 07, 2019
Unprecedented high and durable MRD negativity in elderly patients with comorbidities.
June 07, 2019
An interview with Sara A. Hurvitz, MD, director of Breast Cancer Clinical Research Program at UCLA Jonsson Comprehensive Cancer Center.
June 06, 2019
David Graham, MD, says that immunotherapy is here to stay.
June 06, 2019
An on-site interview with Åsmund Avdem Fretland, MD.
June 06, 2019
An interview with Hedy L. Kindler, MD, regarding the benefit of olaparib in BRCA-positive disease.
June 06, 2019
Phase 3 data show significant benefit over symptom management alone.
June 05, 2019
Addition to gemcitabine failed to improve DFS.
June 05, 2019
Post hoc analysis of frailty subgroups from phase 3 ASPIRE and ENDEAVOR.
June 05, 2019
First alternative to topotecan emerges in single-group phase 2 study.
June 05, 2019
98% reduction in peripheral blasts at day 3.
June 05, 2019
High-quality response and MRD negativity also seen with KRd12.
June 05, 2019
Adding ipilimumab to nivolumab boosts major pathologic response rate.
June 05, 2019
High rate of disenrollment because of adverse events.
June 05, 2019
Phase 3 MYSTIC data also support PD-L1 expression as a marker for OS.
June 04, 2019
Findings add to growing evidence for immune-mediated mechanism of action.
June 04, 2019
4-cycle regimen offers similar survival benefit.
June 04, 2019
Combination was approved by FDA on May 28, 2019.
June 04, 2019
ARAMIS data also show extended metastasis-free survival.
June 04, 2019
ADMIRAL study shows survival benefit across major ITD3 comutations.
June 04, 2019
Multicenter study shows benefit in certain patients with stage 1 disease.
June 03, 2019
Interim analysis of a pilot study shows encouraging pathologic response rate.
June 03, 2019
Cancer specialists presented thousands of studies at this year’s ASCO meeting. Univadis journalists chose the most clinically relevant ones and summarized them in our easy-to-scan bullet-point format.
Expert Commentary
Dr. Richard L. Schilsky
June 14, 2019

Univadis is a free, time-saving medical news & education community designed exclusively for healthcare professionals. Unique executive summaries tame the onslaught of medical literature and keep clinicians up to date in just a few minutes per day. Concise, interactive educational presentations from our experts help clinicians stay on top of practice-changing research and trends, and collaborate with colleagues at any time, on any device.

Aptus Health does not endorse and is not responsible for the accuracy of the content, or for practices or standards of non-Aptus Health sources.

Copyright © 2019 Aptus Health, Inc. All rights reserved. Version 2.14.541.14

Contact Us

(888) 729-4546
Monday - Friday 8am to 7pm ET

support@univadis.com